OA10999A - Pharmaceutical compositions containing an effervescent acid-base couple - Google Patents
Pharmaceutical compositions containing an effervescent acid-base couple Download PDFInfo
- Publication number
- OA10999A OA10999A OA9900061A OA9900061A OA10999A OA 10999 A OA10999 A OA 10999A OA 9900061 A OA9900061 A OA 9900061A OA 9900061 A OA9900061 A OA 9900061A OA 10999 A OA10999 A OA 10999A
- Authority
- OA
- OAPI
- Prior art keywords
- pharmaceutical composition
- composition according
- effervescent
- daims
- tablets
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 239000003826 tablet Substances 0.000 claims abstract description 38
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 26
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 claims abstract description 24
- 239000007938 effervescent tablet Substances 0.000 claims abstract description 24
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000001530 fumaric acid Substances 0.000 claims abstract description 13
- 230000002378 acidificating effect Effects 0.000 claims abstract description 6
- 238000007907 direct compression Methods 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 4
- 239000011976 maleic acid Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 16
- 239000008101 lactose Substances 0.000 claims description 15
- 239000000314 lubricant Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- -1 colourings Substances 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 238000004040 coloring Methods 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 25
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 20
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 15
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 12
- 239000008118 PEG 6000 Substances 0.000 description 10
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 10
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 108010011485 Aspartame Proteins 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 239000000605 aspartame Substances 0.000 description 7
- 235000010357 aspartame Nutrition 0.000 description 7
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 7
- 229960003438 aspartame Drugs 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 229960004205 carbidopa Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229960004502 levodopa Drugs 0.000 description 5
- 229960002702 piroxicam Drugs 0.000 description 5
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940001089 sinemet Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 239000001747 Potassium fumarate Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- SHPKCSFVQGSAJU-SEPHDYHBSA-L potassium fumarate Chemical compound [K+].[K+].[O-]C(=O)\C=C\C([O-])=O SHPKCSFVQGSAJU-SEPHDYHBSA-L 0.000 description 2
- 235000019295 potassium fumarate Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 229910000599 Cr alloy Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000738583 Senna artemisioides Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940082170 ibuprofen 200 mg Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960001794 melevodopa Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000011182 sodium carbonates Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI001746A IT1293764B1 (it) | 1997-07-23 | 1997-07-23 | Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA10999A true OA10999A (en) | 2001-11-07 |
Family
ID=11377613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA9900061A OA10999A (en) | 1997-07-23 | 1999-03-19 | Pharmaceutical compositions containing an effervescent acid-base couple |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6284272B1 (cs) |
| EP (1) | EP1003486B1 (cs) |
| JP (1) | JP4801255B2 (cs) |
| KR (1) | KR100528141B1 (cs) |
| CN (1) | CN1138535C (cs) |
| AT (1) | ATE232092T1 (cs) |
| AU (1) | AU743186B2 (cs) |
| BG (1) | BG64074B1 (cs) |
| BR (1) | BR9801335B1 (cs) |
| CZ (1) | CZ296221B6 (cs) |
| DE (1) | DE69811236T2 (cs) |
| DK (1) | DK1003486T3 (cs) |
| EA (1) | EA002608B1 (cs) |
| ES (1) | ES2191960T3 (cs) |
| HU (1) | HU226115B1 (cs) |
| IL (1) | IL134166A (cs) |
| IT (1) | IT1293764B1 (cs) |
| NO (1) | NO326639B1 (cs) |
| NZ (1) | NZ502479A (cs) |
| OA (1) | OA10999A (cs) |
| PL (1) | PL199164B1 (cs) |
| PT (1) | PT1003486E (cs) |
| SI (1) | SI1003486T1 (cs) |
| SK (1) | SK284551B6 (cs) |
| TR (1) | TR199900675T1 (cs) |
| WO (1) | WO1999004765A2 (cs) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040151768A1 (en) * | 1997-07-23 | 2004-08-05 | Chiesi Farmaceutici S.P.A. | Pharmaceutical compositions containing an effervescent acid-base couple |
| FR2786395A1 (fr) * | 1998-12-01 | 2000-06-02 | Virbac Sa | Compositions seches solubles en presence d'eau et evitant la reaction de maillard a l'etat sec, leur preparation et leurs applications |
| CA2378525A1 (en) * | 1999-07-02 | 2001-01-11 | Sca Lohnherstellungs Ag | A solid formulation of glucosamine sulphate |
| AU5060499A (en) * | 1999-08-04 | 2001-03-05 | Ranbaxy Laboratories Limited | Hydrodynamically balanced oral drug delivery system |
| IN190018B (cs) * | 1999-09-28 | 2003-05-31 | Panacea Biotec Ltd | |
| GB0006897D0 (en) * | 2000-03-23 | 2000-05-10 | Smithkline Beecham Plc | Medicaments |
| DK1309315T3 (da) * | 2000-08-18 | 2006-10-09 | Pharmacia Corp | Hurtigt disintegrerende oral valdecoxib-formulering |
| CN1638739A (zh) * | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| US6531153B2 (en) * | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
| US6762153B2 (en) * | 2001-10-18 | 2004-07-13 | Rohm And Haas Company | Delivery system for cyclopropenes |
| US20030091627A1 (en) * | 2001-10-31 | 2003-05-15 | Vinay Sharma | Rate-controlled delivery of macrolides |
| KR100456273B1 (ko) | 2001-11-16 | 2004-11-10 | 김용년 | 산과 반응하여 일정 속도로 이산화탄소를 발생시킬 수있는 고상 제제 및 그의 제조 방법 |
| US7488496B2 (en) * | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
| EP1490024B1 (en) | 2002-03-06 | 2012-01-18 | EffRx Pharmaceuticals SA | Effervescent compositions comprising alendronate |
| BG730Y1 (bg) * | 2003-03-20 | 2005-04-30 | Владимир НАЙДЕНОВ | Ефервесцентна лекарствена форма |
| CN100445263C (zh) * | 2003-04-24 | 2008-12-24 | 四川大学 | 甘氨酸钠碳酸盐的微波合成方法 |
| FR2876911B1 (fr) * | 2004-10-21 | 2007-04-13 | Pierre Fabre Medicament Sa | Complexe comprenant du piroxicam, une cyclodextrine et de l'arginine |
| PL1729813T3 (pl) | 2004-04-01 | 2011-09-30 | Pf Medicament | Kompleksy inkluzyjne zawierające piroksykam, cyklodekstrynę i argininę |
| CA2566384C (en) * | 2004-05-28 | 2010-08-03 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| CA2613631A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
| CN100341488C (zh) * | 2005-11-22 | 2007-10-10 | 瑞普（保定）生物药业有限公司 | 一种饮水免疫泡腾片及其制备方法 |
| WO2007059591A1 (en) * | 2005-11-28 | 2007-05-31 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| WO2008079404A2 (en) * | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| MX2009011973A (es) * | 2007-05-08 | 2009-12-10 | Hercules Inc | Formulacion robusta de tabletas que se desintegran con rapidez. |
| JP5783725B2 (ja) | 2007-12-28 | 2015-09-24 | インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． | レボドパの放出制御製剤及びその使用 |
| US9629809B2 (en) | 2008-07-21 | 2017-04-25 | Si Group, Inc. | High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms |
| EP2309988B1 (en) | 2008-07-21 | 2015-11-25 | SI Group, Inc. | High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms |
| RU2552927C2 (ru) * | 2010-03-13 | 2015-06-10 | Истпонд Лабораториз Лимитед | Жиросвязывающая композиция |
| CN101836951B (zh) * | 2010-05-20 | 2013-06-05 | 山东达因海洋生物制药股份有限公司 | 一种含盐酸氨溴索的口服溶液及其制备方法 |
| CN102322123B (zh) * | 2011-06-30 | 2013-09-18 | 德清艺玛工艺装饰有限公司 | 一种仿大理石泡沫装饰材料 |
| CN102398378A (zh) * | 2011-11-03 | 2012-04-04 | 北京华禧联合科技发展有限公司 | 镀铬冲模在硫酸氢氯吡格雷片制备过程中的应用 |
| WO2014093073A1 (en) * | 2012-12-14 | 2014-06-19 | Albemarle Corporation | High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| MX369315B (es) | 2013-10-07 | 2019-11-05 | Impax Laboratories Inc | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. |
| EP2870961B1 (en) * | 2013-11-06 | 2018-07-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Effervescent formulations of pramipexole |
| MA52122A (fr) | 2018-03-02 | 2021-04-28 | Chiesi Farm Spa | Formulation pharmaceutique pour administration intraduodénale comprenant de la mélévodopa et de la carbidopa |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| US12194150B2 (en) | 2020-12-22 | 2025-01-14 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1196033B (it) * | 1984-02-22 | 1988-11-10 | Chiesi Farma Spa | Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche |
| ATE76747T1 (de) * | 1986-06-10 | 1992-06-15 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| CH675537A5 (cs) * | 1988-03-25 | 1990-10-15 | Ciba Geigy Ag | |
| DE3838431A1 (de) * | 1988-11-12 | 1990-05-17 | Bayer Ag | Ibuprofen-brausezubereitungen |
| EP0443381B2 (en) * | 1990-02-14 | 1997-10-22 | Takeda Chemical Industries, Ltd. | Effervescent composition, its production and use |
| US5252341A (en) * | 1990-07-16 | 1993-10-12 | Degussa Aktiengesellschaft | Tablets and granulates containing mesna as active substance |
| JP2910425B2 (ja) * | 1992-06-17 | 1999-06-23 | 和光純薬工業株式会社 | 発泡性錠剤の新規な製造方法 |
| JP3170139B2 (ja) * | 1994-04-08 | 2001-05-28 | エスエス製薬株式会社 | 発泡性錠剤 |
| FR2733420B1 (fr) * | 1995-04-28 | 1997-06-27 | Sep Tarral | Preparations pectiques utilisables comme support de medicament |
| WO1997044017A1 (en) * | 1996-05-17 | 1997-11-27 | Merck & Co., Inc. | Effervescent bisphosphonate formulation |
-
1997
- 1997-07-23 IT IT97MI001746A patent/IT1293764B1/it active IP Right Grant
-
1998
- 1998-03-10 BR BRPI9801335-1A patent/BR9801335B1/pt not_active IP Right Cessation
- 1998-07-23 DK DK98941377T patent/DK1003486T3/da active
- 1998-07-23 PT PT98941377T patent/PT1003486E/pt unknown
- 1998-07-23 IL IL13416698A patent/IL134166A/xx not_active IP Right Cessation
- 1998-07-23 EA EA200000062A patent/EA002608B1/ru not_active IP Right Cessation
- 1998-07-23 KR KR10-2000-7000710A patent/KR100528141B1/ko not_active Expired - Lifetime
- 1998-07-23 DE DE69811236T patent/DE69811236T2/de not_active Expired - Lifetime
- 1998-07-23 WO PCT/EP1998/004517 patent/WO1999004765A2/en not_active Ceased
- 1998-07-23 CZ CZ20000255A patent/CZ296221B6/cs not_active IP Right Cessation
- 1998-07-23 AT AT98941377T patent/ATE232092T1/de active
- 1998-07-23 EP EP98941377A patent/EP1003486B1/en not_active Expired - Lifetime
- 1998-07-23 HU HU0003897A patent/HU226115B1/hu unknown
- 1998-07-23 SK SK92-2000A patent/SK284551B6/sk not_active IP Right Cessation
- 1998-07-23 TR TR1999/00675T patent/TR199900675T1/xx unknown
- 1998-07-23 US US09/463,224 patent/US6284272B1/en not_active Expired - Lifetime
- 1998-07-23 AU AU89777/98A patent/AU743186B2/en not_active Ceased
- 1998-07-23 JP JP2000503825A patent/JP4801255B2/ja not_active Expired - Fee Related
- 1998-07-23 SI SI9830384T patent/SI1003486T1/xx unknown
- 1998-07-23 PL PL338502A patent/PL199164B1/pl not_active IP Right Cessation
- 1998-07-23 NZ NZ502479A patent/NZ502479A/en not_active IP Right Cessation
- 1998-07-23 ES ES98941377T patent/ES2191960T3/es not_active Expired - Lifetime
- 1998-07-23 CN CNB988082624A patent/CN1138535C/zh not_active Expired - Fee Related
-
1999
- 1999-03-15 BG BG103253A patent/BG64074B1/bg unknown
- 1999-03-19 OA OA9900061A patent/OA10999A/en unknown
- 1999-03-22 NO NO19991376A patent/NO326639B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA10999A (en) | Pharmaceutical compositions containing an effervescent acid-base couple | |
| JP7216055B2 (ja) | 医薬組成物 | |
| AU2001252953B2 (en) | Stable thyroid hormone preparations and method of making same | |
| EP2251005B1 (en) | Orally disintegrating tablets | |
| EP1863443B1 (en) | Rapidly disintegrating dosage form comprising magnesium carbonate heavy | |
| EP1133298B1 (en) | Compositions comprising cefuroxime axetil | |
| US6667056B2 (en) | Pharmaceutical compositions containing an effervescent acid-base couple | |
| JP4965130B2 (ja) | 乾式直打速崩壊性錠剤 | |
| US20100047184A1 (en) | Pharmaceutical compositions containing an effervescent acid-base couple | |
| CA2719608A1 (en) | Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors | |
| WO2004089343A1 (en) | Water soluble tablets | |
| WO1999039730A1 (en) | Oral preparations containing peptides promoting the secretion of growth hormone | |
| CA2297673C (en) | Pharmaceutical compositions containing an effervescent acid-base couple | |
| MXPA00000754A (en) | Pharmaceutical compositions containing an effervescent acid-base couple | |
| JPWO2007049626A1 (ja) | カベルゴリン含有経口固形製剤 | |
| JP2022097443A (ja) | ビラスチンを含有する口腔内崩壊錠 | |
| HK1029525B (en) | Pharmaceutical compositions containing an effervescent acid-base couple |